ABSTRACT

Objective: The objective of the present study was to formulate and development of a novel self-emulsifying drug delivery system to enhance the solubility thereby improving the relative bioavailability of a BCS class II drug Lumefantrine. Methods: A series of Lumefantrine containing self-nanoemulsifying formulations F1-F9 were prepared using peceol as oil phase, labrasol as surfactant and PEG 400 as cosurfactant, respectively. Lumefantrine was identified by ultraviolet–visible spectroscopy at ?max of 234 nm and FTIR study. All formulation were subjected toinvitro parameters such as dispersibility test, droplet size analysis, viscosity, zeta potential and dissolution study. The optimized formulation F5 was kept for stability studies. Results: Optimized formulation showed drug release (99.13%) with droplet size (33.84 nm), Zeta potential (-22.2 mV), viscosity (156.2 cP) and infinite dilution capability. In-vitro drug release of the was highly significant as compared to pure drug. Conclusion: The present SEDDS would be a promising novel system to improve the lipophilic drug’s dissolution rate and potentially the bioavailability. Keywords: lipophilic drugs, Solubility, Bioavailability, Self emulsifying drug delivery system, surfactant
Publication date: 01/12/2020

https://ijbpas.com/pdf/2020/December/MS_IJBPAS_2020_5280.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.12.5280